Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 5 Breast Neoplasms 3 Prostatic Neoplasms 2 Fallopian Tube Neoplasms 2 Uterine Neoplasms 1 Sarcoma 1 Pancreatic Neoplasms 1 Neoplasm Metastasis 1 Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1 MMR-D/MSI-H Colorectal Cancers 1 Lymphoma 1 Leiomyosarcoma 1 Glioblastoma 1 Endometrial Neoplasms 1 Cystadenocarcinoma, Serous 1 Colorectal Neoplasms 1 Cholangiocarcinoma 1

Interventions

Gemcitabine 2 Docetaxel 2 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2 olaratumab 1 niraparib 1 Trabectedin 1 Doxorubicin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Leiomyosarcoma × niraparib × Clear all

NCT05174455 2023-09-18

Niraparib for the Treatment of Leiomyosarcoma

Ohio State University Comprehensive Cancer Center

Phase 2 Withdrawn

Leiomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡